Contents

Search

recombinant factor VIII; turoctocog alfa; (Factorate, Recombinate, Xyntha, Kogenate FS, Kovaltry, NovoEight)

Tradenames: Factorate, Recombinate, Xyntha (from CHO cells) Indications: - management of hemophilia A Contraindications: - hypersensitivity to mouse proteins (preparation contains trace amounts of mouse protein Pregnancy category: C Safety in lactation: ? Dosage: 1) individualize dose based upon coagulation studies 2) one unit will increase circulating AHF by 2% 3) hospitalized patients: a) 20-50 units/kg/dose b) may be given every 12-24 hours & more frequently in special circumstances AHF units = body weight (kg) x desired AHF increase (%) x 0.5 Injection: 250, 500, 1000 units. Pharmacokinetics: - elimination: liver - elimination 1/2life 4-24 hours (biphasic) Adverse effects: - uncommon (< 1%) - flushing, tachycardia, headache, nausea/vomiting, paresthesia, allergic vasomotor reactions, tightness in neck or chest

Specific

lonoctocog alfa; rVIII SingleChain (Afstyla) simoctocog alfa (Nuwiq)

General

coagulation factor VIII; antihemophilic factor; AHF; procoagulant component; contains: factor VIIIa heavy chain, 200 kD & 92 isoforms; factor VIII B chain; factor VIIIa light chain (F8, F8C) recombinant protein; chimer

References

  1. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  2. Brooks M FDA Clears Factor VIII Product Kovaltry for Hemophilia. Medscape March 17, 2016 http://www.medscape.com/viewarticle/860577
  3. Al-Salama ZT, Scott LJ. Lonoctocog Alfa: A Review in Haemophilia A. Drugs. 2017 Oct;77(15):1677-1686. PMID: 28900904 Free PMC Article

Component-of

recombinant factor VIII/von Willebrand factor